JP6852079B2 - 架橋粒子 - Google Patents

架橋粒子 Download PDF

Info

Publication number
JP6852079B2
JP6852079B2 JP2018538068A JP2018538068A JP6852079B2 JP 6852079 B2 JP6852079 B2 JP 6852079B2 JP 2018538068 A JP2018538068 A JP 2018538068A JP 2018538068 A JP2018538068 A JP 2018538068A JP 6852079 B2 JP6852079 B2 JP 6852079B2
Authority
JP
Japan
Prior art keywords
particles
crosslinked
drug
independently
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018538068A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019500403A (ja
JP2019500403A5 (cg-RX-API-DMAC7.html
Inventor
デベデック フランツ レ
デベデック フランツ レ
クリスティン ジェーン アレン
クリスティン ジェーン アレン
デイビッド マイケル スティーブンス
デイビッド マイケル スティーブンス
ディーン ジェームズ レイジャー‐アギアール
ディーン ジェームズ レイジャー‐アギアール
ティモシー トーデラ ルカ
ティモシー トーデラ ルカ
カール エリック エルムキスト
カール エリック エルムキスト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2019500403A publication Critical patent/JP2019500403A/ja
Publication of JP2019500403A5 publication Critical patent/JP2019500403A5/ja
Priority to JP2021037974A priority Critical patent/JP7104198B2/ja
Application granted granted Critical
Publication of JP6852079B2 publication Critical patent/JP6852079B2/ja
Priority to JP2022109826A priority patent/JP7500659B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018538068A 2015-10-09 2016-10-07 架橋粒子 Active JP6852079B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021037974A JP7104198B2 (ja) 2015-10-09 2021-03-10 架橋粒子
JP2022109826A JP7500659B2 (ja) 2015-10-09 2022-07-07 架橋粒子

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562239758P 2015-10-09 2015-10-09
US62/239,758 2015-10-09
US201662281631P 2016-01-21 2016-01-21
US62/281,631 2016-01-21
US201662313013P 2016-03-24 2016-03-24
US62/313,013 2016-03-24
PCT/US2016/056135 WO2017062871A1 (en) 2015-10-09 2016-10-07 Crosslinked particles

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021037974A Division JP7104198B2 (ja) 2015-10-09 2021-03-10 架橋粒子

Publications (3)

Publication Number Publication Date
JP2019500403A JP2019500403A (ja) 2019-01-10
JP2019500403A5 JP2019500403A5 (cg-RX-API-DMAC7.html) 2019-11-14
JP6852079B2 true JP6852079B2 (ja) 2021-03-31

Family

ID=58488602

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018538068A Active JP6852079B2 (ja) 2015-10-09 2016-10-07 架橋粒子
JP2021037974A Active JP7104198B2 (ja) 2015-10-09 2021-03-10 架橋粒子
JP2022109826A Active JP7500659B2 (ja) 2015-10-09 2022-07-07 架橋粒子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021037974A Active JP7104198B2 (ja) 2015-10-09 2021-03-10 架橋粒子
JP2022109826A Active JP7500659B2 (ja) 2015-10-09 2022-07-07 架橋粒子

Country Status (7)

Country Link
US (3) US10258578B2 (cg-RX-API-DMAC7.html)
EP (2) EP4019575B1 (cg-RX-API-DMAC7.html)
JP (3) JP6852079B2 (cg-RX-API-DMAC7.html)
CN (1) CN109843996B (cg-RX-API-DMAC7.html)
AU (2) AU2016335866B2 (cg-RX-API-DMAC7.html)
ES (2) ES2906596T3 (cg-RX-API-DMAC7.html)
WO (1) WO2017062871A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4019575B1 (en) 2015-10-09 2023-12-06 Le Dévédec, Frantz Crosslinked particles
US11905377B2 (en) 2019-01-17 2024-02-20 Pendant Biosciences, Inc. Factors controlling drug release in cross-linked poly(valerolactone) based matrices
WO2021127623A1 (en) * 2019-12-19 2021-06-24 Pendant Biosciences, Inc. Crosslinked pla-based copolymers
US20250215215A1 (en) * 2022-03-29 2025-07-03 Kaneka Corporation Thermoplastic resin composition
EP4506395A4 (en) * 2022-03-29 2026-04-15 Kaneka Corp CROSS-CUT RESIN PARTICLES AND THEIR PRODUCTION PROCESS
US20250388748A1 (en) * 2022-03-29 2025-12-25 Kaneka Corporation Thermoplastic resin composition
JPWO2025075122A1 (cg-RX-API-DMAC7.html) * 2023-10-04 2025-04-10

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003219922B2 (en) * 2002-02-27 2009-09-10 Pharmain Corporation Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US6800663B2 (en) * 2002-10-18 2004-10-05 Alkermes Controlled Therapeutics Inc. Ii, Crosslinked hydrogel copolymers
US8808681B2 (en) 2006-06-05 2014-08-19 Massachusetts Institute Of Technology Crosslinked, degradable polymers and uses thereof
CN100546661C (zh) * 2006-12-01 2009-10-07 华南理工大学 一种原位成孔自固化磷酸钙复合组织工程支架的制备方法
US20130142733A1 (en) * 2007-11-05 2013-06-06 Vanderbilt University Multifunctional degradable nanoparticles with control over size and functionalities
US20110274620A1 (en) * 2007-11-05 2011-11-10 Harth Eva M Multifunctional degradable nanoparticles with control over size and functionalities
DK2209496T3 (da) 2007-11-05 2019-08-05 Univ Vanderbilt Multifunktionelle nedbrydelige nanopartikler med kontrol over størrelse og funktioner
CN103003260A (zh) 2009-12-21 2013-03-27 赢创德固赛有限公司 用于制备包含不饱和官能团的环酯的方法和由其制备的聚酯
WO2013169938A2 (en) * 2012-05-08 2013-11-14 Vanderbilt University Polycarbonate containing compounds and methods related thereto
ITTO20130431A1 (it) * 2013-05-28 2014-11-29 Fond Istituto Italiano Di Tecnologia Copolimero e nanoparticelle da esso ottenute per la veicolazione di un farmaco
WO2016174116A1 (en) 2015-04-27 2016-11-03 Eggplant S.R.L. Polyester composition and method for producing the same
EP4019575B1 (en) 2015-10-09 2023-12-06 Le Dévédec, Frantz Crosslinked particles

Also Published As

Publication number Publication date
US20190262274A1 (en) 2019-08-29
CA3001329A1 (en) 2017-04-13
EP3359591A1 (en) 2018-08-15
JP7500659B2 (ja) 2024-06-17
AU2016335866A1 (en) 2018-05-17
US20170100343A1 (en) 2017-04-13
CN109843996A (zh) 2019-06-04
EP3359591A4 (en) 2019-05-29
EP4019575A1 (en) 2022-06-29
EP4019575B1 (en) 2023-12-06
ES2973475T3 (es) 2024-06-20
EP3359591B1 (en) 2021-12-01
JP2021102622A (ja) 2021-07-15
CN109843996B (zh) 2022-09-06
WO2017062871A1 (en) 2017-04-13
JP2019500403A (ja) 2019-01-10
US10258578B2 (en) 2019-04-16
AU2021202965A1 (en) 2021-06-03
JP2022130727A (ja) 2022-09-06
JP7104198B2 (ja) 2022-07-20
US11426356B2 (en) 2022-08-30
US20230190664A1 (en) 2023-06-22
ES2906596T3 (es) 2022-04-19
AU2016335866B2 (en) 2021-02-11
AU2021202965B2 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
JP7104198B2 (ja) 架橋粒子
WO2019108030A1 (ko) 안정성 및 저장 안정성이 향상된 생분해성 미립구의 제조방법
Yang et al. Synthesis, self-assembly, and in vitro doxorubicin release behavior of dendron-like/linear/dendron-like poly (ε-caprolactone)-b-poly (ethylene glycol)-b-poly (ε-caprolactone) triblock copolymers
Wischke et al. Controlled drug release from biodegradable shape-memory polymers
AU2011280348A1 (en) Method for preparing microspheres and microspheres produced thereby
JP2007182442A (ja) 結晶質の相で治療用の薬剤を含有している高分子組成物、およびその形成の方法
Lim Soo et al. Polycaprolactone-block-poly (ethylene oxide) Micelles: A Nanodelivery System for 17β-Estradiol
JP2023511978A (ja) 外膜又は外膜周囲の神経アブレーションのための徐放性マトリックス及びその使用
JP2019500403A5 (cg-RX-API-DMAC7.html)
Bertram et al. Using polymer chemistry to modulate the delivery of neurotrophic factors from degradable microspheres: delivery of BDNF
Sandker et al. Degradation, intra-articular retention and biocompatibility of monospheres composed of [PDLLA-PEG-PDLLA]-b-PLLA multi-block copolymers
Vatankhah et al. Seed's morphology-induced core-shell composite particles by seeded emulsion polymerization for drug delivery
CN113473973A (zh) 含有地洛瑞林的缓释注射剂及其制备方法
Amani et al. Preparation and pulsatile release evaluation of teriparatide-loaded multilayer implant composed of polyanhydride-hydrogel layers using spin coating for the treatment of osteoporosis
JP2011518812A (ja) チオエステル結合を有するポリマーを含む粒子
Ali et al. Nanoclay reinforced ternary blends based on biodegradable polymers for drug delivery application
JP2009545351A (ja) 拡張期間を超えての皮下移植片の有効成分の遊離
HK40009686B (en) Crosslinked particles
HK40009686A (en) Crosslinked particles
JP5131652B2 (ja) ポリグリセロールデンドリマーの3次元架橋物及び3次元架橋方法、並びにこれを用いたヒドロゲル、薬物送達システム
Rashid et al. Fabrication and in vitro evaluation of novel pH‐sensitive poly (2‐methoxyethyl methacrylate‐co‐itaconic acid) microgels
Sehra et al. Formulation and evaluation of sustained release microspheres of poly-lactide-co-glycolide containing tamoxifen citrate
JP7580139B2 (ja) デスロレリンを含む徐放性注射用組成物
JP7730130B2 (ja) 塞栓材及びその製造方法
Salehi Polymer blends as a route for controlled drug release

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210310

R150 Certificate of patent or registration of utility model

Ref document number: 6852079

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250